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Abstract
Background: Among diabetics, those with kidney disease 
have exceptionally high rates of cardiovascular (CV) morbid-
ity and mortality, and progression of their underlying dis-
ease. Finerenone is a novel, non-steroidal, selective miner-
alocorticoid-receptor antagonist which has shown to re-
duce albuminuria in type 2 diabetes (T2D) patients with 
chronic kidney disease (CKD), while revealing only a low risk 
of hyperkalemia. However, the effect of finerenone on renal 
and CV outcomes has not been investigated in long-term 
trials yet. Methods: The Finerenone in Reducing Kidney Fail-
ure and Disease Progression in Diabetic Kidney Disease 
 (FIDELIO-DKD) trial aims to assess the efficacy and safety of 
finerenone compared to placebo at reducing clinically im-
portant renal and CV outcomes in T2D patients with CKD. 
FIDELIO-DKD is a randomized, double-blind, placebo-con-
trolled, parallel-group, event-driven trial running in 47 coun-
tries with an expected duration of approximately 5.5 years. 
FIDELIO-DKD randomized 5,734 patients with an estimat-
ed glomerular filtration rate (eGFR) ≥25–< 75 mL/min/1.73 
m2 and albuminuria (urinary albumin-to-creatinine ratio 
≥30–≤5,000 mg/g). The study has at least 90% power to de-
tect a 20% reduction in the risk of primary outcome (overall 
two-sided significance level α = 0.05), the composite of time 
to first occurrence of kidney failure, a sustained decrease of 
eGFR ≥40% from baseline over at least 4 weeks, or renal 
death. Conclusion: FIDELIO-DKD will determine whether an 
FIDELIO-DKD Phase 3 investigators and site list are included in the 
online supplementary files
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
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Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
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optimally treated cohort of T2D patients with CKD at high 
risk of renal and CV events will experience cardiorenal ben-
efits with the addition of finerenone to their treatment reg-
imen. © 2019 The Author(s)
Published by S. Karger AG, Basel
Background
Worldwide, over 2.5 million people receive renal re-
placement therapy, and this number is projected to grow 
and be more than double in 2030 [1]. Type 2 diabetes 
(T2D) is the most common cause of end-stage renal dis-
ease (ESRD) in the Western world, except for Taiwan, 
which has a higher prevalence of ESRD than the US [2]. 
Moreover, this trend in ESRD is rapidly increasing in Asia 
and Latin America [1].
The current pharmacological strategy to reduce the rate 
of progression of kidney disease is the optimization of 
blood pressure control, lipid levels, and glycemic control, 
and has been in place since the 1990s [3]. Following the 
advent of the angiotensin-receptor blocker (ARB) trials al-
most 20 years ago [4, 5], the sodium-glucose cotransport-
er-2 (SGLT2) inhibitor canagliflozin added to a renin – an-
giotensin system (RAS) blocker recently demonstrated a 
34% relative risk reduction of the renal-specific composite 
endpoint of ESRD, a doubling of creatinine level, or death 
from renal causes [6]. For many years, T2D patients 
who have chronic kidney disease (CKD) and albuminuria 
> 300 mg/day have had guideline directives to use angio-
tensin-converting enzyme inhibitors (ACEIs) or ARBs [7, 
8]. From mid-June 2019 onwards, SGLT2 inhibitors have 
been recommended in addition for patients with T2D with 
albuminuria > 300 mg/g if their estimated glomerular fil-
tration rate (eGFR) is > 30 mL/min/1.73 m2, to reduce car-
diovascular (CV) events, with increasing evidence that 
they may also slow kidney disease progression [9].
While optimizing therapy with RAS blockers and SGLT2 
inhibitors has markedly slowed CKD progression, it has 
not stopped it fully [6, 10]. Despite the use of ACEIs, ARBs, 
and the concomitant use of SGLT2 inhibitors, the rate of 
ESRD remains unacceptably high, with more than twice the 
normal decline in kidney function [6]. Mineralocorticoid 
receptor antagonists (MRAs) such as spironolactone dem-
onstrate renoprotective effects in preclinical studies [11, 
12] and are known to reduce albuminuria and blood pres-
sure in patients with kidney disease, well-documented sur-
rogates of CKD progression in men [13–15]. Thus, antago-
nism of mineralocorticoid receptor (MR) might be effec-
tive in slowing CKD progression in T2D [16–19].
Finerenone is a novel, non-steroidal, selective MRA 
that has much greater MR selectivity than spironolactone 
and better MR affinity than eplerenone in vitro [20]. Fur-
thermore, unlike spironolactone and eplerenone, which 
reach higher concentrations in renal tissue in comparison 
to cardiac tissue [21], finerenone is distributed relatively 
equally between the heart and the kidney, at least in ro-
dents [22]. Lastly, its non-steroidal structure allows it to 
bind to the MR with high affinity and to inhibit recruit-
ment of transcriptional co-activators involved in the ex-
pression of hypertrophic and pro-fibrotic genes more ef-
fectively than steroidal MRAs [23, 24]. This unique bind-
ing mode and lack of other hormonal stimulation 
compared to spironolactone mitigates against untoward 
effects like gynecomastia [25, 26].
In a trial involving T2D patients with a clinical diagnosis 
of CKD (Mineralocorticoid-Receptor Antagonist Tolera-
bility Study-Diabetic Nephropathy), finerenone compared 
to placebo showed only small mean changes in serum potas-
sium and a low incidence of hyperkalemia leading to a low 
number of discontinuations with no evidence of a dose – 
response relationship. Furthermore, finerenone compared 
to placebo demonstrated a statistically significant reduction 
in urinary albumin-to-creatinine ratio (UACR) at doses 
starting from 7.5 mg on top of standard of care (including 
an ACEI or ARB) after 90 days of treatment [27].
These findings provided the rationale for initiating a 
large-scale Phase III program with finerenone investigat-
ing renal and CV outcomes in T2D patients with all stag-
es of CKD in 2 large-scale outcome trials. In this study, 
we describe the design of the Finerenone in reducing Kid-
ney Failure and Disease Progression in Diabetic Kidney 
Disease trial (FIDELIO-DKD; ClinicalTrials.gov identi-
fier: NCT02540993) and present the baseline characteris-
tics of enrolled patients.
Patients and Methods
General Description
FIDELIO-DKD is an international, multicenter, randomized, 
double-blind, placebo-controlled, parallel-group, event-driven 
study, formally designed to assess whether finerenone reduces car-
diorenal morbidity and mortality in T2D patients with CKD when 
used in addition to standard of care.
Study Population
The inclusion and exclusion criteria are summarized in Table 
1. Patients included in the trial are aged ≥18 years with T2D and a 
clinical diagnosis of CKD, pre-treated with ACEIs or ARBs for at 
least 4 weeks before the run-in visit, and had serum potassium 
≤4.8 mEq/L at both the run-in and screening visits. Patients had to 
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Table 1. Inclusion and exclusion criteria
Inclusion criteria Written informed consent signed before any study-specific procedure
Men or women aged 18 years and older
Women of child-bearing potential with a negative pregnancy test and agreeing to use adequate contraception
Patients with T2D mellitus as defined by the American Diabetes Association
Patients with a clinical diagnosis of CKD based on either of the following criteria at the run-in and screening visits:
– Persistent high albuminuria defined as UACR ≥30 mg/g (≥3.4 mg/mmol) but <300 mg/g (<33.9 mg/mmol) and 
eGFR ≥25 but <60 mL/min/1.73 m2 (CKD-EPI) and presence of diabetic retinopathy in the medical history
or
– Persistent very high albuminuria defined as UACR ≥300 mg/g (≥33.9 mg/mmol) and eGFR ≥25 but <75 mL/
min/1.73 m2 (CKD-EPI)
Prior treatment with ACEIs and ARBs
Serum potassium ≤4.8 mmol/L at both the run-in and screening visits
Exclusion criteria
Medical and surgical history Known significant non-diabetic renal disease, including clinically relevant renal artery stenosis
UACR >5,000 mg/g (>565 mg/mmol) at the run-in or screening visit
Glycosylated hemoglobin >12% (>108 mmol/mol) at the run-in or screening visit
Uncontrolled arterial hypertension with mean sitting SBP ≥170 mm Hg or mean sitting DBP ≥110 mm Hg at the 
run-in visit or mean sitting SBP ≥160 mm Hg or mean sitting DBP ≥100 mm Hg at the screening visit
SBP <90 mm Hg at the run-in or screening visit
Patients with a clinical diagnosis of chronic heart failure with reduced ejection fraction and persistent symptoms 
(New York Heart Association class II–IV) at the run–in visit
Stroke, transient ischemic cerebral attack, acute coronary syndrome, or hospitalization for worsening heart failure, in 
the 30 days before the screening visit
Dialysis for acute renal failure in the 12 weeks before the run-in visit
Renal allograft in place or a scheduled kidney transplant in the 12 months after the run-in visit
Known hypersensitivity to the study treatment (active substance or excipients)
Addison’s disease
Hepatic insufficiency classified as Child-Pugh C
Medication and drug use Concomitant therapy with eplerenone, spironolactone, any renin inhibitor, or potassium-sparing diuretic which 
cannot be discontinued at least 4 weeks before the screening visit
Concomitant therapy with both ACEIs and ARBs which cannot be discontinued for the purpose of the studies
Concomitant therapy with potent cytochrome P450 isoenzyme 3A4 inhibitors or inducers (to be stopped at least
7 days before randomization)
Other Any other condition or therapy which would make the patient unsuitable for the studies and would not allow 
participation for the full planned study period (e.g., active malignancy or other condition limiting life
expectancy to <12 months)
Pregnant or breast-feeding or intention to become pregnant during the studies
Previous assignment to treatment during the studies
Previous (within 30 days before randomization) or concomitant participation in another clinical study
(i.e., Phase I–III clinical studies) with investigational medicinal product, except for participation in the
run-in and screening periods of Studies 17,530 and 16,244
Close affiliation with the investigational site: for example, a close relative of the investigator or dependent person 
(e.g., employee or student of the investigational site)
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; DKD, 
diabetic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; UACR, urine albumin-to-creati-
nine ratio; T2D, type 2 diabetes.
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have persistent high albuminuria (defined as UACR ≥30 but <300 
mg/g), eGFR ≥25 but < 60 mL/min/1.73 m2, and presence of dia-
betic retinopathy in the medical history, or persistent very high 
albuminuria (defined as UACR ≥300 mg/g) and eGFR ≥25 but <75 
mL/min/1.73 m2.
Two recruitment caps were pre-specified and closed per region. 
The first cap limited the randomization of patients with high albu-
minuria and diabetic retinopathy in the medical history to approx-
imately 10% of all patients randomized. The second cap limited the 
randomization of patients with very high albuminuria and eGFR 
60–75 mL/min/1.73 m2 to 10% of all patients randomized with 
very high albuminuria at screening.
Study Design
The study design of FIDELIO-DKD is illustrated in Figure 1. 
After signing the informed consent, a run-in visit was performed. 
If the patient met all inclusion criteria and none of the exclusion 
criteria, a mandatory run-in period that could last between a min-
imum of 4 and a maximum of 16 weeks started. At the end of the 
run-in period, a screening visit to confirm the patient’s eligibility 
again took place, with subsequent randomization within 2 weeks.
To account for the high variability of UACR and eGFR, patients 
were permitted to switch either after the run-in or screening visit 
between FIDELIO-DKD and the second study of the program, Fi-
nerenone in Reducing Cardiovascular Mortality and Morbidity in 
Diabetic Kidney Disease (FIGARO-DKD; ClinicalTrials.gov iden-
tifier: NCT02545049), before being randomized. As CKD in T2D is 
a disease continuum and variations in eGFR and UACR within the 
boundaries of this disease continuum do not affect the clinical risk, 
the switching of patients before randomization was deemed justi-
fied and necessary to reduce the burden on candidate study par-
ticipants (run-in and screening assessments were not repeated after 
switching). A switchover from either trial was permitted only once.
Due to the anticipated recruitment period of > 2 years and the 
progressive nature of the underlying disease, re-screening was per-
mitted once. Conditions for re-screening were amended in 2017 to 
shorten the re-screening period from 6 to 3 months and to allow 
re-screening even if the reason for the initial screen failure was an 
elevated blood potassium value (serum potassium > 4.8 mEq/L).
Eligible patients were randomized 1: 1 via an interactive tele-
phone/web-based system to receive once-daily treatment with ei-
ther finerenone or placebo. Treatment assignment was determined 
by computer-generated random sequence with stratification by re-
gion (North America, Latin America, Europe, Asia, Other), eGFR 
category at screening (25–< 45, 45–< 60, and ≥60 mL/min/1.73 m2), 
and category of albuminuria at screening (high or very high).
The starting dose of study drug was selected based on eGFR mea-
sured at the screening visit: patients started on finerenone 10 mg/
day or matching placebo if their eGFR was 25–< 60 mL/min/1.73 m2; 
if their eGFR was ≥60 mL/min/1.73 m2, the starting dose was 20 mg/
day. Up-titration of study drug to 20 mg/day is permitted at any time 
after Visit 2 (Month 1), down-titration to 10 mg/day at any time af-
ter start of treatment. Patients are instructed to take the study drug 
tablet orally, once daily at approximately the same time every day.
Central laboratory values, including serum potassium and se-
rum creatinine, were obtained at all study visits and used for con-
Switching to
FIGARO allowed 
Treatment according to national guidelines
including either ACEI or ARB but not both
Informed
consent Randomization
Double-blind treatment period
Study termination 
decision
Run-in period
4–16 weeks
Mandatory
Screening
period
Up to 14
days
Run-in
visit
Screening
visit Visit 1
Placebo
Finerenone 10 mg once daily if eGFR at screening <60 mL/min/1.73 m2
Finerenone 20 mg once daily if eGFR at screening ≥60 mL/min/1.73 m2
Visit 2
Month 1
Visit 3
Month 4
Visit n
every 4 months
until study
terminationa
End-of-study
visit upon 
study
terminationb
Post-treatment
visit 4 weeks 
+5 days after 
last dose of 
study drugc
Up- and down-titration according to
potassium and eGFR changes
Fig. 1. Study design of FIDELIO-DKD. a Scheduled visits will con-
tinue even if the study drug treatment is discontinued; b End-of-
study visit will take place only after the sponsor has officially ter-
minated the study; c For all patients who have received the study 
drug. ACEI, angiotensin-converting enzyme inhibitor; ARB, an-
giotensin-receptor blocker; eGFR, estimated glomerular filtration 
rate; FIGARO, Finerenone in Reducing Cardiovascular Mortality 
and Morbidity in Diabetic Kidney Disease. 
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firmation of patients’ eligibility, safety monitoring, renal endpoint 
reporting, and end-of-study statistical analysis. From Visit 1 on-
wards, blood potassium and serum creatinine are measured at all 
on-treatment visits at a local laboratory. The investigators are in-
structed to use these local values for dose titrations and safety mon-
itoring. Patients’ safety is monitored with physical examinations 
(including measurements of weight and vital signs) and 12-lead 
electrocardiograms at regular intervals throughout the study. Pa-
tients are assessed for adverse events and study endpoints at each 
visit and are requested to complete health-related quality-of-life 
questionnaires (EQ-5D-5L and Kidney Disease Quality of Life) at 
baseline and yearly thereafter.
The study protocol was approved by International Review 
Boards, independent Ethics Committees, and competent authori-
ties according to national and international regulations. FIDELIO-
DKD is conducted in accordance with the ICH Harmonised Tri-
partite Guideline for Good Clinical Practice. All study participants 
provided written informed consent before entering the study.
Objectives and Endpoints
The primary endpoint of FIDELIO-DKD is a composite of time 
to first occurrence of kidney failure, a sustained decrease of eGFR 
≥40% from baseline over at least 4 weeks, or renal death. The com-
ponent kidney failure is defined as either the occurrence of ESRD 
or eGFR < 15 mL/min/1.73 m2, confirmed by a second measure-
ment at the earliest 4 weeks after the initial measurement. ESRD is 
defined as the initiation of chronic dialysis (hemo- or peritoneal 
dialysis) for at least 90 days or renal transplantation. The eGFR 
threshold of 15 mL/min/1.73 m2 is consistent with the definition 
of kidney failure from Kidney Disease: Improving Global Out-
comes [28] and was chosen to include an objective component to 
the endpoint because the decision to initiate dialysis therapy or 
kidney transplantation may be affected by factors other than eGFR.
The main pre-specified secondary endpoint is a composite of 
time to first occurrence of CV mortality and morbidity, as mea-
sured by the composite endpoint of time to first occurrence of CV 
death, non-fatal myocardial infarction, non-fatal stroke, or hospi-
talization for heart failure.
Other secondary endpoints include time to all-cause mortality, 
time to all-cause hospitalization, change in UACR from baseline 
to 4 months, and a composite endpoint of time to first occurrence 
of kidney failure or sustained decrease in eGFR ≥57% from base-
line over at least 4 weeks or renal death.
Statistical Considerations
Statistical Analyses
The primary efficacy endpoint for the statistical analysis is the 
time to first occurrence of the composite of onset of (i) kidney fail-
ure, (ii) a sustained decrease of eGFR ≥40% from baseline over at 
least 4 weeks, or (iii) renal death. Events included in the primary 
analysis will be counted from the day of randomization onwards 
until the planned end-of-study visit following the study sponsor’s 
decision to terminate the study. Patients without a primary effi-
cacy endpoint event will be censored at the date of their last contact 
with complete information on all components of the primary com-
posite endpoint (up to and including the end-of-study visit). In 
case a non-renal death occurs within 5 months from the last visit 
(4 monthly visits plus maximum allowed time window of 30 days) 
and a subsequent clinic visit had been planned, the non-renal 
death date will be used as the censoring date.
To test for superiority of finerenone over placebo in prolonging 
the time to the first primary efficacy endpoint event, the null hy-
pothesis of equal hazards in the 2 treatment groups will be evalu-
ated via a log-rank test, stratified by the stratification factors re-
gion, eGFR category at screening, and category of albuminuria at 
screening. The treatment effect will be expressed as a hazard ratio 
with a corresponding confidence interval from a stratified Cox re-
gression model. The statistical analyses will follow the intention-
to-treat principle and will be based primarily on the full analysis 
set, consisting of all randomized patients considered valid for anal-
ysis. An analysis on the per protocol set, excluding patients with 
relevant deviations from the protocol, will be conducted as a sen-
sitivity analysis in which only events occurring within 30 days after 
permanent treatment discontinuation will be considered.
To control the multiplicity arising from multiple tests, a weighted 
Bonferroni-Holm procedure will be used for the primary renal effi-
cacy endpoint and the key secondary CV endpoint, followed by a 
hierarchical testing procedure of further secondary efficacy end-
points (as in the order given above). The weights assigned to the pri-
mary efficacy endpoint and the key secondary endpoint are given as 
2/3 and 1/3, resulting in a minimal local two-sided alpha level of 
3.3333 and 1.6667%, respectively, which will be increased to 5% for 
one test if the null hypothesis for the other test can be rejected. The 
full alpha level of 5% will be passed along hierarchically to the further 
secondary endpoints in a serial gatekeeping approach, that is, if and 
only if both the primary endpoint and the key secondary endpoint 
show significance. Within the hierarchy of the secondary endpoints, 
the full alpha is forwarded to the next null hypothesis as long as the 
previous null hypothesis is rejected, otherwise confirmatory testing 
stops at this point. As described under Powering and Sample Size, the 
actual significance levels used during the final analysis will be slight-
ly adjusted based on the formal interim analysis. The testing strategy 
is further illustrated in Figure 2. To declare the study successful, it will 
be considered sufficient to reject the null hypothesis related to the 
primary renal endpoint or key secondary CV endpoint.
Powering and Sample Size
As an event-driven study, FIDELIO-DKD has a power of 90% 
to detect a 20% relative risk reduction of finerenone versus placebo 
in the primary efficacy endpoint (equaling a hazard ratio of 0.8) 
based on a total of 1,068 patients with primary renal events and 
applying the log-rank test at a two-sided significance alpha level of 
3.3333%. Further assumptions at the planning stage included an 
annual placebo event rate of 12% (assumed to be unaffected by 
treatment discontinuations), a common annual lost-to-follow-up 
rate of 0.7% in both treatment groups, an annual finerenone dis-
continuation rate of 5%, and a total treatment duration between 
44 and 48 months, consisting of a recruitment period of 33 and 
41 months with an equal recruitment pattern during the accrual 
period and a maximum treatment period of the last recruited pa-
tient of 11 and 7 months, respectively. Taking the ramp-up time 
during recruitment into consideration, this leads to an estimated 
required number of approximately 4,800 patients to be random-
ized. Assuming a screening failure rate of 50%, 9,600 patients need 
to be screened. To account for the lower-than-assumed event rates 
for the primary endpoint as observed during the conduct of the 
trial, the originally planned number of randomized patients was 
increased by approximately 1,000 patients.
One formal interim analysis is planned to be conducted when 
approximately 712 primary efficacy endpoint events (i.e., 2/3 of the 
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finally intended number) have been observed. To guide the deci-
sion regarding early stopping of the study for success at the interim 
analysis, the Haybittle-Peto rule will be used, requiring a two-sid-
ed p value below 0.00270 for both the null hypotheses correspond-
ing to the primary renal efficacy endpoint and the key secondary 
CV endpoint to be rejected and leading to a minimal alpha adjust-
ment for the respective tests at the final analysis stage. Addition-
ally, for lack of efficacy, a non-binding futility approach will be 
used to allow stopping the study at the interim analysis stage if the 
conditional power of rejecting the null hypothesis related to the 
primary endpoint at the final stage given the interim data falls to 
an unacceptably low level of 10% or less.
Additional Statistical Considerations
For analysis, Austria, Belgium, Denmark, Finland, France, 
 Germany, Ireland, Italy, Netherlands, Norway, Portugal, Spain, 
Sweden, Switzerland, and the United Kingdom are considered in 
Western Europe; Bulgaria, Czech Republic, Greece, Hungary, 
Lithuania, Poland, Romania, Russia, Slovakia, Turkey, and Ukraine 
in Eastern Europe.
Results
Recruitment of patients for FIDELIO-DKD began in 
September 2015 and was completed in June 2018. A total 
of 13,911 individuals, including 604 patients who were re-
screened, were enrolled at 1,062 sites in 47 countries, re-
sulting in 5,734 randomized patients. During the run-in or 
screening phase but before randomization, 1,374 patients 
switched over from FIGARO-DKD. The rate of screening 
failure in all patients enrolled was 58.8 and 14.9% in pa-
tients who switched. Sixty patients in FIDELIO-DKD were 
excluded from the full analysis set due to substantial Good 
Clinical Practice violations, resulting in 5,674 patients 
(99.0%) in whom the primary analysis will be performed.
More than 40% of the patients were recruited in 
 Europe, with a similar number in Western and Eastern 
Europe, 16.6% in North America, 10.5% in Latin  America, 
27.8% in Asia, and 3.5% in Australia, New Zealand, and 
South Africa (region “Other”).
The overall trial population is predominately male 
(70.2%) and white (65.9%), with a mean age of 65.6 years 
and a mean duration of diabetes of 16.6 years. At baseline, 
mean glycosylated hemoglobin was 7.7%, mean eGFR 
44.3 mL/min/1.73 m2, mean serum potassium 4.4 mEq/L, 
and median UACR 851 mg/g. Most patients (88.4%) had 
eGFR < 60 mL/min/1.73 m2 and 54.9% eGFR < 45 mL/
min/1.73 m2; the majority of patients (87.4%) had very 
high albuminuria at baseline.
At baseline, 3,727 patients (65.7%) were taking ARBs 
and 1,942 (34.2%) ACEIs, as requested by the protocol, 
and almost all patients (97.4%) were on glucose-lowering 
Time to primary renal
composite event
Time to all-cause
mortality
Time to cardiovascular
composite event
Weighted
Bonferroni-Holm
Serial gatekeeping:
α is passed on only if H1 and H2 are rejected
Hierarchical
testing
α = 0.05
H2
w2 = 1/3
1
1
1
H1
w1 = 2/3
H3
w3 = 0 1
Time to all-cause
hospitalization
H4
w4 = 0 1
Change in UACR from
baseline to month 4
H5
w5 = 0
Time to secondary
renal composite event
H6
w6 = 01
Fig. 2. Statistical testing strategy of primary and secondary efficacy endpoints for FIDELIO-DKD. UACR, urinary albumin-to-creati-
nine ratio.
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medication. Approximately 2/3 (64.1%) were using insu-
lin, while metformin was the most frequently used glu-
cose-lowering oral drug at baseline. Glucagon-like pep-
tide 1 agonists were used by 7.0% of patients, while 4.5% 
were using SGLT2 inhibitors.
At baseline, nearly all patients (97.0%) had arterial hy-
pertension as concomitant disease, and 46.8% had dia-
betic retinopathy. Less than half (45.9%) had CV disease 
(CVD) in the medical history: 29.8% had coronary artery 
disease, 13.5% myocardial infarction, 12.1% ischemic 
stroke, 16.2% peripheral artery disease, and 1.3% had a 
carotid endarterectomy. Only 7.5% of all patients suffered 
from heart failure at baseline, which is related to the pro-
tocol-requested exclusion of all patients with heart failure 
with reduced ejection fraction with New York Heart As-
sociation class II–IV at run-in and screening. Further in-
formation about the baseline characteristics can be found 
in Table 2 and in online supplementary Table S1 (see 
www.karger.com/doi/10.1159/000503713).
Discussion
Treatment of CKD in general has evolved over the last 
few decades, resulting in a slowing of progression of kid-
ney disease from 10 to 12 mL/min/year to approximately 
2 mL/min/year in patients with an eGFR < 60 mL/min/1.73 
m2, normal decline being around 0.7–0.9 mL/min/year 
Total (n = 5,674)
Age, years, mean (SD) 65.6 (9.1)
Gender, male, n (%) 3,984 (70.2)
Race, n (%)
White 3,738 (65.9)
Asian 1,434 (25.3)
Black/African American 267 (4.7)
Othera 216 (3.8)
Region, n (%)
Europe 2,358 (41.6)
Western Europe 1,251 (22.0)
Eastern Europe 1,107 (19.5)
North America 944 (16.6)
Latin America 593 (10.5)
Asia Pacific 1,579 (27.8)
Other 200 (3.5)
BMI, kg/m2, mean (SD) 31.1 (6.0)
Duration of diabetes, years, mean (SD) 16.6 (8.8)
Systolic blood pressure, mm Hg, mean (SD) 138 (14)
Diastolic blood pressure, mm Hg, mean (SD) 76 (10)
Heart rate, beats/min, mean (SD) 72 (11)
eGFR (CKD-EPI), mL/min/1.73 m2, mean (SD) 44.3 (12.6)
eGFR (CKD-EPI), mL/min/1.73 m2, n (%)
≥60 656 (11.6)
45 to <60 1,900 (33.5)
25 to <45 2,981 (52.5)
<25 135 (2.4)
Median UACR, mg/g (25th–75th percentile) 851 (446–1,634)
UACR category, mg/g, n (%)
<30 25 (0.4)
30 to <300 685 (12.1)
≥300 4,960 (87.4)
Serum potassium, mEq/L, mean (SD) 4.4 (0.5)
HbA1c, %, mean (SD) 7.7 (1.3)
ACEIs, n (%) 1,942 (34.2)
ARBs, n (%) 3,727 (65.7)
Total (n = 5,674)
Beta-blockers, n (%) 2,963 (52.2)
Diuretics, n (%) 3,210 (56.6)
Loop diuretics 1,618 (28.5)
Thiazide diuretics 1,356 (23.9)
Calcium antagonists, n (%) 3,585 (63.2)
Statins, n (%) 4,213 (74.3)
Platelet aggregation inhibitors, n (%) 3,222 (56.8)
Glucose-lowering therapies, n (%) 5,526 (97.4)
Insulin 3,636 (64.1)
Metformin 2,486 (43.8)
Acarbose 323 (5.7)
Sulfonylurea 1,329 (23.4)
DPP-4 inhibitors 1,521 (26.8)
GLP-1 agonists 395 (7.0)
SGLT2 inhibitors 258 (4.5)
Arterial hypertension, n (%) 5,501 (97.0)
Diabetic retinopathy, n (%) 2,657 (46.8)
Diabetic neuropathy, n (%) 1,448 (25.5)
Lipid metabolism disorders, n (%) 2,546 (44.9)
History of CV disease, n (%) 2,602 (45.9)
Coronary artery disease 1,693 (29.8)
Peripheral arterial disease 920 (16.2)
Myocardial infarction 765 (13.5)
Ischemic stroke 685 (12.1)
Carotid endarterectomy 71 (1.3)
Heart failure, n (%) 423 (7.5)
a American Indian/Alaska Native, Native Hawaiian/other Pacific 
Islander or multiple entries.
BMI, body mass index; eGFR, estimated glomerular filtration rate; 
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; 
UACR, urine albumin-to-creatinine ratio; HbA1c, hemoglobin A1c; 
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin 
receptor blocker; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-
like peptide 1; SGLT2, sodium-glucose cotransporter-2; CV, cardiova-
scular.
Table 2.  Baseline characteristics
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[10]. Newer treatments to help glycemic control have also 
translated into further slowing of CKD progression 
(eGFR decline of 1.85 mL/min/year) as well as further re-
duction of CV events in T2D patients [6, 29]. However, 
despite this promising progress T2D patients with CKD 
still exhibit residual cardiorenal morbidity and mortality.
Since 2001, numerous trials assessing various agents 
with a variety of mechanisms have failed to slow CKD 
progression over RAS blockers. Attempts were made to 
reduce the high CV and renal risk in patients already tak-
ing RAS inhibitor monotherapy by adding a second RAS 
blocker: in the Veterans Affairs Nephropathy in Diabetes 
trial, an ACEI in combination with an ARB [30], and in 
the Aliskiren Trial in T2D using Cardiorenal Endpoints, 
the combination of an ARB with the renin inhibitor 
aliskiren were investigated [31]. Dual RAS blockade in-
creased the frequency of serious adverse events such as 
acute kidney injury, hyperkalemia, or stroke, and there-
fore cannot be recommended in T2D patients with CKD.
More recently, the Canagliflozin and Renal Events in 
Diabetes with Established Nephropathy Clinical Evalua-
tion study investigating canagliflozin in patients with 
T2D and CKD with very high albuminuria found a 30% 
risk reduction for progression to ESRD, doubling of se-
rum creatinine, or CV or renal death over placebo in pa-
tients already receiving RAS blockers [6]. In a meta-anal-
ysis by Zelniker et al. [32], the effect of SGLT2 inhibitors 
on major adverse CV events (i.e., myocardial infarction, 
stroke, or CV death) and renal outcomes was analyzed. 
SGLT2 inhibitors reduced major adverse CV events by 
11%, with benefit seen only in patients with atheroscle-
rotic CVD (14% risk reduction) and not in those without. 
SGLT2 inhibitors reduced the risk of CV death or hospi-
talization for heart failure by 23%, with a similar benefit 
in patients with and without atherosclerotic CVD and 
with and without a history of heart failure. The magni-
tude of benefit of SGLT2 inhibitors varied with baseline 
renal function and showed a lesser reduction in progres-
sion of renal disease in patients with more severe kidney 
disease at baseline.
The use of SGLT2 inhibitors was very low in general 
when FIDELIO-DKD started recruitment in September 
2015. Despite not restricting the use of SGLT2 inhibitors 
in enrolled patients, it was even lower in the targeted 
study population, since the initiation of treatment 
with  SGLT2 inhibitors in patients with eGFR < 60 mL/
min/1.73 m2 was prohibited, and it was recommended to 
stop treatment with SGLT2 inhibitors in patients with 
eGFR persistently < 45 mL/min/1.73 m2. At baseline, 4.5% 
of all randomized patients were treated with SGLT2 in-
hibitors. During the trial, the use of SGLT2 increased 
slightly but is still low (< 10% of patients). Most likely the 
data collected will not be sufficient for a meaningful sub-
group analysis. However, in previous trials treatment 
with an MRA has never been investigated on top of a RAS 
blocker in this group of non-heart failure patients and 
hence the results of FIDELIO-DKD will be able to gener-
ate hypotheses for further investigations.
Inflammation and fibrosis mediated by MR overacti-
vation are also observed in the kidney [33]. The resulting 
glomerular podocyte injury and mesangial cell prolifera-
tion may manifest as glomerular injury, renal vasocon-
striction, and albuminuria. Targeting MR overactivation 
with MRAs, based on the studies conducted so far, showed 
a sustained reduction in albuminuria of ≥30%, a bio-
marker that has now been validated as surrogate for slow-
ing CKD progression [13, 34, 35]. It is therefore reason-
able to assume that MR blockade, if safe, may offer addi-
tional benefit when added to monotherapy with a RAS 
blocker by attenuating aldosterone breakthrough, and 
through inhibition of deleterious effects of aldosterone, 
such as renal inflammation and fibrosis.
The currently available steroidal MRAs, spironolac-
tone and eplerenone, have been investigated in clinical 
studies that varied between 4 and 52 weeks in duration 
and assessed the effects on albuminuria in different CKD 
populations. However, to date, all studies are plagued 
with hyperkalemia as a major complication of this class. 
In a recent meta-analysis, Yang et al. [36] concluded that 
treatment with spironolactone in patients with moderate 
to severe (stage 3–4) CKD was associated with a lower risk 
of ESRD (relative risk 34%) but was complicated by a 
higher risk of hyperkalemia-associated hospitalization 
(3 times greater risk). They concluded that the renopro-
tective benefit of spironolactone may be offset by the hy-
perkalemia risk. In another clinical study of heart failure 
patients, Trevisan et al. [37] concluded that in an un-
selected cohort of new users of MRAs, hyperkalemia was 
very common and frequently followed by therapy inter-
ruption, especially among participants with CKD. As a 
result, the median time on MRA treatment during the 
initial 12  months of treatment was 179 days (130–
346 days), with 24% of remaining patients on therapy af-
ter 12 months. Participants with CKD were at highest risk 
of hyperkalemia and discontinuation. In an investigation 
analyzing electronic medical records of a diverse US pop-
ulation, Collins et al. [38] found that serum potassium 
elevation even above 5 mEq/L was associated with an in-
crease in CV risk. Hyperkalemia requiring dose reduction 
or even discontinuation of a RAS inhibitor may also have 
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a negative impact on the prognosis in T2D patients with 
CKD or heart failure [38].
Hyperkalemia is a disabler of renal function-preserv-
ing medications. In a post hoc analysis from the Reduc-
tion of Endpoints in NIDDM with the Angiotensin II An-
tagonist Losartan study, Miao et al. [39] demonstrated 
that patients who achieved mean serum potassium 
≥5 mEq/L during follow-up had a 43% higher risk of the 
composite endpoint of doubling of serum creatinine or 
ESRD after controlling for potential confounders. They 
concluded that treatment with losartan is associated with 
a high risk of elevated serum potassium levels in patients 
with diabetes mellitus and nephropathy. These elevated 
serum potassium levels are in turn associated with an in-
creased risk of renal progression and offset the renopro-
tective effects of losartan. Given that the major risk fac-
tors for hyperkalemia are eGFR < 45 mL/min/1.73 m2 or 
serum potassium > 4.5 mEq/L on diuretics [40], it is clear 
that those with CKD in T2D patients will be at highest 
risk, so we restricted recruitment to patients with potas-
sium levels up to 4.8 mEq/L.
Finerenone is a novel, non-steroidal, selective MRA 
that is associated with lower rates of hyperkalemia com-
pared to steroidal MRAs [41]. In the Mineralocorticoid-
Receptor Antagonist Tolerability Study-Diabetic Ne-
phropathy Study, finerenone induced a dose-dependent 
reduction of UACR, with the largest placebo-corrected 
reduction (–38%) in the group being treated with 20 mg 
once daily. Finerenone dosages over 90 days of treatment 
resulted in small declines in eGFR (∼2–4 mL/min/1.73 
m2) and blood pressure (3–5  mm Hg) as well as small 
changes in serum potassium (+0.2 mEq/L) [27].
FIDELIO-DKD is the largest renal study recruited to 
specifically investigate the progression of kidney disease in 
T2D patients with CKD. While the primary focus is on re-
nal outcomes, potential benefits on CV events will be as-
sessed as well. Unlike previous outcome trials where the 
levels of albuminuria and kidney function were advanced 
into stages 3 and 4, FIDELIO-DKD has also included a co-
hort of patients with lower levels of albuminuria (high al-
buminuria defined as UACR ≥30 but < 300 mg/g) and stage 
2 CKD (eGFR 60–75 mL/min/1.73 m2). FIDELIO-DKD is 
part of a larger Phase III program that consists of 2 large-
scale, event-driven outcome trials, FIDELIO-DKD and 
 FIGARO-DKD, an event-driven trial investigating the car-
diorenal effects of finerenone in T2D patients with less ad-
vanced kidney disease. Complemented by the results of 
FIGARO-DKD where even T2D patients with stage 2 CKD 
with high and very high albuminuria and stage 1 CKD pa-
tients with very high albuminuria are included, the pro-
gram will allow evaluation of the effects of finerenone in 
the broadest spectrum of CKD patients with T2D ever in-
vestigated. Finerenone was developed neither as an antihy-
pertensive agent nor as a glucose-lowering drug being re-
purposed for a population with kidney impairment. In-
stead, it was designed to alleviate disease burden in patients 
with cardiorenal diseases, especially in T2D patients.
The results of FIDELIO-DKD will determine whether 
an optimally treated cohort of T2D patients with CKD at 
high risk of progression of their renal disease and CV 
events will experience cardiorenal benefits with the addi-
tion of finerenone to their treatment regimen. Results are 
expected in 2020.
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